Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pki-166. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 19/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 0.78 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.74 |
| ▸ | KDR | P35968 | 1/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.74 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.74 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.74 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.74 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pki-166 SCHEMBL30883827 | 1.00 | EGFR (1.00) | EGFRCSF1RHDAC3KDRHDAC4 | |
| Pki-166 SCHEMBL29352405 | 1.00 | EGFR (1.00) | EGFRCSF1RHDAC3KDRHDAC4 | |
| Pki-166 SCHEMBL9973098 | 1.00 | EGFR (1.00) | EGFRCSF1RHDAC3KDRHDAC4 | |
| Pki-166 SCHEMBL209560 | 1.00 | EGFR (1.00) | EGFRCSF1RHDAC3KDRHDAC4 | |
| Pki-166 SCHEMBL29409570 | 0.99 | EGFR (0.98) | EGFRCSF1RHDAC3KDRHDAC4 | |
| SCHEMBL12308303 | 0.89 | EGFR (0.86) | EGFRCSF1RHDAC3KDRHDAC4 | |
| SCHEMBL4766235 | 0.89 | EGFR (0.86) | EGFRCSF1RHDAC3KDRHDAC4 | |
| SCHEMBL4766237 | 0.89 | EGFR (0.86) | EGFRCSF1RHDAC3KDRHDAC4 | |
| SCHEMBL7499430 | 0.89 | EGFR (0.86) | EGFRCSF1RHDAC3KDRHDAC4 | |
| SCHEMBL4901987 | 0.89 | EGFR (1.00) | EGFRHDAC3KDRHDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2031 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016025641-A1 | COMBINATIONS OF AN ERK INHIBITOR AND AN EGFR INHIBITOR AND RELATED METHODS | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-02-18 | — | — | WO | claimed |
| EP-2207805-B1 | NLRR-1 ANTAGONISTS AND USES THEREOF | GENENTECH INC (US) | 2014-07-09 | — | — | EP | claimed |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG. (DE) | 2010-12-09 | — | — | US | claimed |
| US-20100144639-A1 | USE OF INHIBITORS OF THE EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) / PROSTATIC HYPERTROPHY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | claimed |
| US-20090306072-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | claimed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | claimed |
| US-20090221519-A1 | COMBINATIONS OF RECEPTOR TYROSINE KINASE INHIBITOR WITH AN A1-ACIDIC GLYCOPROTEIN BINDING COMPOUND | NOVARTIS AG (CH) | 2009-09-03 | — | — | US | claimed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | claimed |
| CN-100342853-C | Therapeutic treatment | ASTRAZENECA AB (SE) | 2007-10-17 | — | — | CN | claimed |
| CN-101035540-A | Pharmaceutical combinations containing benzoxazine for treating respiratory diseases | BOEHRINGER INGELHEIM INT (DE) | 2007-09-12 | — | — | CN | claimed |
| WO-2003037897-A2 | USE OF 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES IN THE TREATMENT OF SOLID TUMOR DISEASES | NOVARTIS AG (CH) | 2003-05-08 | — | — | WO | claimed |
| US-20030065000-A1 | Method of treating cancer | COHEN PAMELA SARAH (US) | 2003-04-03 | — | — | US | claimed |
| CN-1100778-C | Pyrrolopyrimidines and process for their preparation | NOVARTIS CO (CH) | 2003-02-05 | — | — | CN | claimed |
| EP-1250140-A2 | COMBINATIONS OF A RECEPTOR TYROSINE KINASE INHIBITOR WITH ALPHA1-ACIDIC GLYCOPROTEIN BINDING COMPOUND | Novartis AG (CH) | 2002-10-23 | — | — | EP | claimed |
| WO-2002050306-A1 | PROCESSES FOR DETERMINING THE BIOLOGICAL ACTIVITY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2002-06-27 | — | — | WO | claimed |
| EP-0836605-B1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2002-02-06 | — | — | EP | claimed |
| WO-2001047507-A2 | COMBINATIONS OF RECEPTOR TYROSINE KINASE INHIBITOR WITH AN A1-ACIDIC GLYCOPROTEIN BINDING COMPOUND | NOVARTIS AG (CH) | 2001-07-05 | — | — | WO | claimed |
| US-6140332-A | Pyrrolopyrimidines and processes for the preparation thereof | NOVARTIS AG (CH) | 2000-10-31 | — | — | US | claimed |
| EP-0836605-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-04-22 | — | — | EP | claimed |
| WO-1997002266-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1997-01-23 | — | — | WO | claimed |